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AbstrAct
Background: Hepatitis E virus (HEV) is an under-recognised aetiological factor of viral hepatitis; it is most 
commonly transmitted via the oral-faecal route, but can also be transmitted by blood or blood products, 
vertically from an infected mother to the foetus or by transplanted organs. The aim of the study was to 
present the current seroprevalence of HEV among soldiers from the Polish Special Forces deployed on 
military operations carried out in harsh environmental conditions.
Materials and methods: The research conducted between October and November 2016 involved 253 active 
duty soldiers, 237 men and 16 women, aged 26–57, without clinical symptoms of infection, participants in 
military operations in Asia and Africa. Accurate HEV diagnosis required the implementation of a two-phase 
diagnostic protocol. During the first phase, immunoenzymatic ELISA method was used to detect specific 
anti-HEV antibodies (IgM and IgG) in blood serum samples indicating contact with an infectious agent in 
the past. During the second phase, serum samples obtained from subjects with positive or inconclusive 
test results were tested again using confirmatory recomLine HEV IgM/IgG immunoassay.
Results: Immunoenzymatic assay found anti-HEV antibodies (IgM and/or IgG) in blood serum samples 
obtained from 18 soldiers. Confirmatory tests were carried out among soldiers tested positive with ELISA 
or those with inconclusive test results; the confirmatory tests showed anti-HEV antibodies (IgM and/or IgG) 
in 16 of the studied soldiers, i.e. 6.3% of the study group.
Conclusions: The occurrence of HEV infections in Polish soldiers justifies the need for the introduction of 
screening tests for HEV in the military environment, especially among blood donors and in cases of whole 
blood or blood products transfusion. 
(Int Marit Health 2018; 69, 2: 137–141)
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INtrODUctION
Military operations involving soldiers from the Polish 
Special Forces are often conducted in areas character-
ised by harsh environmental conditions, where the risk 
for infections, primarily those transmitted through the fae-
cal-oral route, is particularly high. The risk is additionally 
increased by poor standards of sanitation and adverse 
climatic conditions. Although infectious diseases found 
among participants in military operations account for less 
than 3% of all diagnoses, limited laboratory capabilities 
on missions abroad may lead to a misdiagnosis (some 
illnesses presenting with gastrointestinal symptoms and 
diagnosed as non-infectious may, in fact, be of infectious 
aetiology). This assumption is highly probable given the 
fact that over 50% of the military personnel deployed on 
operations overseas report diarrhoea, and the numbers 
of diarrhoea cases surge when hostilities intensify [1]. 
Acute gastrointestinal disorders are also a  common 
health problem in Polish Military Contingents. Nonethe-
less, Polish soldiers reporting such problems only receive 
symptomatic treatment; the underlying cause of their 
illness is rarely identified. After completing their tour of 
duty abroad soldiers return to Poland where they under-
go tests for infectious diseases. However, the number 
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of laboratory tests offered is very limited and include 
microbiological diagnostics for Salmonella-Shigella and 
serological tests for hepatitis A, B, C, and syphilis [2]. 
Since Polish soldiers perform their mandatory tasks in 
areas characterised by poor sanitary standards where infec-
tious diseases are hyperendemic, it is appropriate to stress 
the need to extend laboratory diagnostics aimed at detecting 
infections with different routes of transmission, in partic-
ular food and waterborne diseases, including hepatitis E. 
This seems to be justified by the fact that hepatitis E 
virus (HEV) infections are indeed found among military 
personnel deployed to areas of armed conflicts around 
Asia and Africa [3, 4]. The aim of the study was to present 
the current seroprevalence of HEV among soldiers from the 
Polish Special Forces serving in military operations carried 
out in harsh environmental conditions. 
MAtErIALs AND MEtHODs
EtHIcs
The research project entitled “Prevalence of selected 
infections in the environment of soldiers from the Special 
Forces” was accepted by the Committee on Bioethics at the 
Military Institute of Medicine (Decision No. 41/2016, 15 July 
2016) in accordance with the provisions of the Declaration 
of Helsinki (2013) and the rules elaborated by the European 
Union ‘Good clinical practice for trials on medicinal products 
in the European Community. The rules governing medicinal 
products in the European Community’ (1990) have been 
ratified by the Ethics Committee in Poland (March 1993).
stUDy POPULAtION
The research conducted between October and Novem-
ber 2016 involved 253 active duty soldiers from the Polish 
Special Forces, 237 men and 16 women, aged 26–57, 
without clinical symptoms of infection, participants in mili-
tary operations in Asia and Africa.
LAbOrAtOry PrOcEDUrEs
Detection of HEV infections required the implementation 
of a two-phase diagnostic protocol. During the first phase, 
immunoenzymatic ELISA test (Euroimmun, Germany) was 
used to detect specific anti-HEV antibodies (IgM and IgG) in 
blood serum samples indicating contact with an infectious 
agent in the past (according to manufacturer’s instructions, 
results equal to or higher than 2.2 IU/mL have been inter-
preted as positive). During the second phase, whole blood 
samples were taken from subjects with positive or incon-
clusive test results, and tested with confirmatory recomLine 
HEV IgM/IgG immunoassay (Mikrogen, Germany; sensitivity 
HEV IgM 93.3%, HEV IgG 96.6%; specificity HEV IgM 96.9%, 
HEV IgG 97.1%). In soldiers tested positive with the ELISA, 
apart from performing confirmatory recomLine HEV IgM/IgG 
immunoassays, we have attempted to detect HEV RNA in 
blood specimens (GeneProof, Czech Republic). This meth-
od, however, proved unsuccessful and did not confirm the 
positive results, which might have been associated with 
only a brief presence of HEV RNA in blood.  
stAtIstIcAL ANALysIs
The statistical analysis has been performed using the 
statistical suite StatSoft. Inc. (2011) Statistica (data analysis 
software system), version 10.0 (SN JGNP3087539302AR-E) 
and Excel. The quantitative variables were characterised 
by the arithmetic mean of standard deviation or median 
or maximum/minimum (range). Statistical significance of 
differences between two groups (unpaired variables model) 
was processed with the t-Student test (or Welch test in the 
case of lack of homogeneity) or Mann-Whitney U test (in cas-
es where conditions of performing the t-Student test were 
not satisfied or for variables measured by ordinal scale). 
Chi-squared tests for independence were used for qualita-
tive variables. The qualitative variables were presented with 
the use of count and percentage. All tests were considered 
significant at p = 0.05.
rEsULts
Immunoenzymatic assays carried out among 253 Polish 
soldiers found anti-HEV antibodies IgM in 2 blood serum 
samples and anti-HEV antibodies IgG in 17 samples. A to-
tal of 18 subjects tested positive for anti-HEV antibodies 
(1 soldier was positive for both anti-HEV antibodies IgM and 
IgG), they accounted for 7.1% of the study group. 
During the second phase of the study task, confirma-
tory tests using recomLine HEV IgM/IgG immunoassay 
were carried out on whole blood samples taken from 
18 of the soldiers, whose ELISA test results were positive 
(Table 1). 
Confirmatory tests performed with recomLine HEV IgM/ 
/IgG assay found anti-HEV antibodies IgM (active infection) 
in 2 study subjects and anti-HEV antibodies IgG (contact 
with an infectious agent in the past) in 16 subjects. A total 
of 16 study patients tested positive for anti-HEV antibod-
ies (2 soldiers tested positive for both anti-HEV IgM and 
IgG), accounted for 6.3% of the entire study group. The 
socio-demographic variables of the 253 soldiers tested 
with the ELISA and confirmatory recomLine HEV assays are 
presented in Table 2. 
The differences among the HEV-infected vs. HEV non-in-
fected as regards the consumption of food and water from 
uncontrolled sources, consumption of pork or seafood, 
presence or absence of clinical symptoms (abdominal pain, 
nausea, vomiting, diarrhoea, fever, myalgia/arthralgia, jaun-
dice), blood treatment in the past, vaccination against hep-
atitis A and B — were not statistically significant. 
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Table 1. Positive and inconclusive test results in soldiers tested for hepatitis E virus (HEV) infections with the ELISA and recomLine 
assays (n = 18)
Anti-HEV IgM ELIsA Anti-HEV IgG ELIsA RecomLine HEV IgM RecomLine HEV IgG Number of results
Negative Positive Negative Positive 13
Negative Positive Negative Negative 2
Positive Borderline Positive Positive 1
Positive Positive Positive Positive 1
Borderline Positive Negative Positive 1
Table 2. Socio-demographic variables of soldiers tested for  
hepatitis E virus (HEV) infection with the ELISA and recomLine 
assays (n = 253)
socio-demographic 
variables
HEV  
infected  
(n = 16)
HEV non- 
-infected  
(n = 237)
P
Age [years] 0.4451
Mean ± standard 
deviation
36.7 ± 5.5 38.1 ± 5.3
Range 29.0–45.0 26.0–57.0
Gender     0.2502
Women 2 (12.5%) 13 (5.5%)
Men 14 (87.5%) 224 (94.5%)
Consumption of water and food  
from uncontrolled sources
0.4842
Yes 5 (31.3%) 95 (40.1%)
No 11 (68.7%) 142 (59.9%)
Symptoms     0.8054
No symptoms 15 (93.8%) 225 (94.9%)
Abdominal pain, 
nausea, vomiting, 
diarrhoea
1 (6.2%) 9 (3.8%)
Fever, myalgia/  
/arthralgia, jaundice
0 (0.0%) 3 (1.3%)
Consumption of pork     0.8970
Yes 15 (93.8%) 224 (94.5%)
No 1 (6.2%) 13 (5.5%)
Consumption of 
seafood
0.8640
Yes 10 (62.5%) 143 (60.3%)
No 6 (37.5%) 94 (39.7%)
History of blood 
treatment
    0.4018
Yes 0 (0.0%) 10 (4.2%)
No 16 (100.0%) 227 (95.8%)
Vaccination against 
hepatitis A and B
    0.0699
Yes 11 (68.8%) 203 (85.7%)
No 5 (31.2%) 34 (14.3%)
DIscUssION
Hepatitis E virus is an under-recognised aetiological fac-
tor of viral hepatitis, which is primarily transmitted via the 
faecal-oral route (consumption of contaminated water or 
food), but can also be acquired by whole blood or blood prod-
ucts, vertically from an infected mother to the foetus or by 
transplanted organs. The risk for HEV infection is significantly 
higher in areas lacking proper hygiene and sanitation during 
the preparation of meals but also in all places around the 
world where virological screening of infected blood or blood 
products is unavailable. The most common classification of 
HEV identifies four main genotypes of the virus. Genotypes 
1 and 2 are usually associated with outbreaks of HEV in-
fections in humans reported from developing countries in 
Asia, Africa, and Central America (faecal-oral transmission). 
Genotype 3 (Europe, Northern America, Australia) and gen-
otype 4 (Japan, China) are a major cause of infections in 
industrialised countries (oral route with zoonotic transmis-
sion as a result of the consumption of contaminated under-
cooked meat, particularly pork). Humans and their infected 
excrement remain the main reservoir and the major source 
of genotypes 1 and 2 HEV infections, whereas genotypes 
3 and 4 are primarily transmitted from animals (especially 
swine and wild boar) but sometimes also humans. Each year, 
an estimated 20 million people acquire the HEV infection 
globally; tens of thousands die from hepatitis E [5, 6]. The 
infection, which is most often asymptomatic, may cause 
an acute self-limiting hepatitis, with symptomatic infection 
more commonly reported among older men (> 50 years) 
[6, 7]. Clinical signs of hepatitis E include nausea, vomiting, 
malaise, loss of appetite, and jaundice [8, 9]; but non-hepatic 
manifestations may also be seen, including a wide spectrum 
of neurological syndromes [10, 11]. HEV infection may pose 
a serious threat to human life and health, especially in pa-
tients with drug-induced immunosuppression, solid organ 
recipients, AIDS patients, the elderly (natural immunosup-
pression), and pregnant women (during the 3rd trimester an 
acute HEV infection may progress into fulminant hepatitis 
with the mortality rate reaching 25%) [12].
The incidence of HEV infections has been steadily in-
creasing over the last decade, mainly in high-income pop-
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ulations [13, 14], which may undoubtedly be associated 
with the transfer of infected immigrants from developing 
countries in the absence of virological screening among 
the newcomers. In the general populations of selected 
European countries, anti-HEV IgG rate ranges from 7.3% 
in Catalonia, Spain [15], 9.2% in Sweden [16], to 16.8% in 
Germany [17]. Some countries have reported a high sero-
prevalence of HEV-positive blood donors, e.g. France and 
the Netherlands [18, 19]. Also, extensive screening which 
has recently been carried out in Poland (12,664 donations 
from 22 blood transfusion centres) demonstrated high prev-
alence of HEV infections in blood donors [20].
Current knowledge about the prevalence of HEV in Po-
land is limited to the reports on specific antibody detection 
in wild animals [21], patients [22, 23], hunters [24], and 
2 studies concerning blood donors [20, 25]. The major 
studies carried out by Grabarczyk et al. [20] indicated a high 
level of HEV endemicity throughout Poland, which justifies 
the urgent need for protection of blood or blood products 
recipients against transfusion-transmitted HEV infection 
as well as the need for further population-based studies 
in order to assess the actual HEV prevalence in the Polish 
population.  
This study, involving soldiers from the Polish Special 
Forces deployed on military operations carried out in harsh 
environmental conditions, had a number of limitations. The 
study group represented only 50% of the total manpower of 
the pre-selected military unit and approx. 10% of the Polish 
Special Forces manpower. The tests were performed in sol-
diers who have never been screened for HEV seroprevalence 
before: hence, it was impossible to determine where they 
had acquired the infection (the study participants have been 
repeatedly deployed on military operations overseas). The 
differences among the HEV-infected vs. HEV non-infected 
soldiers as regards the consumption of food and water 
from uncontrolled sources, blood treatment in the past, and 
preventive measures (vaccination against hepatitis A and B, 
avoiding the consumption of pork and seafood in dining 
facilities of poor sanitary standards) were not statistically 
significant. Therefore, it was impossible to determine wheth-
er there was any connection between risk factors/health 
prevention and HEV occurrence. For accurate assessment of 
HEV seroprevalence in the Polish Armed Forces, especially 
in soldiers deployed on operations in harsh environmental 
conditions, it is necessary to extend the diagnostic panel of 
laboratory tests performed before and after deployment into 
the theatre of operations (preferably a two-phase diagnostic 
protocol: ELISA test for detection of specific anti-HEV IgM 
and IgG antibodies + confirmatory recomLine HEV IgM/IgG 
immunoassay in case of positive or inconclusive results), 
which will make it possible to identify carriers and symptom-
atic patients with non-specific gastrointestinal disorders, 
who may be the source of infection for other people in their 
local population.  
cONcLUsIONs
The occurrence of HEV infections in Polish soldiers justi-
fies the need for the introduction of screening tests for HEV 
in the military environment, especially among blood donors 
and whole blood or blood products recipients. 
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